key: cord-0972700-4zxoy6zw
authors: Amer, M. R.; Bawazeer, M.; Maghrabi, K.; Kamal, A. M.; Butt, A.; Dahhan, T.; Kseibi, E.; Abujazar, M.; Alghunaim, R.; Rabee, M.; Abualkhair, M.; Al-Janoubi, A.; AlFirm, A.; Khurshid, S. M.; Gajic, O.; Walkey, A. J.; Mosier, J. M.; Zabolotskikh, I. B.; Gavidia, O. Y.; Teruel, S. Y.; Bernstein, M. A.; Boman, K.; Kumar, V. K.; Bansal, V.; Kashyap, R.
title: Clinical Characteristics and Outcomes of Critically ill Mechanically Ventilated COVID-19 Patients Receiving interleukin-6 Receptor Antagonists and/or Corticosteroid Therapy, the INTERACT study: A Multicenter International Observational Study
date: 2021-04-13
journal: nan
DOI: 10.1101/2021.04.12.21255323
sha: 41d5fd6d4e20e432a7f6cc9a549b67b6e448fdf9
doc_id: 972700
cord_uid: 4zxoy6zw

Objectives: To compare the clinical characteristics and outcomes of critically ill coronavirus disease (COVID-19) patients requiring mechanical ventilation (MV), receiving interleukin 6 receptor (IL6R) antagonists, steroids, or a combination of both. Design: An international, multicenter, observational study derived from the COVID-2019 Viral Infection and Respiratory Illness University Study (VIRUS) registry and conducted through the Discovery Network, the Society of Critical Care Medicine. Marginal structural modeling was used to adjust for time-dependent confounders, and observations were weighted using the inverse probability of treatment weight. Sensitivity analysis was conducted to emulate a target trial design. Setting: 168 hospitals in 16 countries. Patients: adult ICU patients ( > 18 years) requiring MV for COVID-19 between March 01, 2020, and January 10, 2021. Intervention: None. Measurements and Main Results: A total of 860 patients met eligibility criteria: 589 received steroids, 170 IL-6R antagonists, and 101 combination therapy, and the groups were balanced after adjustment. The median daily steroid dose was 7.5 mg dexamethasone or equivalent (IQR: 6 to 14 mg); 80.8% received low-dose and 19.2% high-dose steroids (> 15 mg/day of dexamethasone or equivalent). The median C-reactive protein level was > 75 mg/L in majority of our cohort. The use of IL6R antagonists alone or in combination was not associated with a significant difference in ventilator free days (VFD) compared to steroids alone (adjusted incidence rate ratio [95% CI]): IL6R antagonists (1.12 [0.88,1.4]), combination (0.83 [0.6,1.14]). Patients treated with low or high-dose steroids had non-significant differences in VFD compared to IL6R antagonists (beta= 0.62, 95% CI -1.54, 2.78 for low-dose steroid; beta= -1.19, 95% CI -3.85, 1.47 for high-dose steroid). The use of IL6R antagonists alone or in combination was not associated with a significant difference in 28 day mortality compared to steroids alone (adjusted odds ratio [95% CI]): IL6R antagonists alone (0.68 [0.44,1.07]), combination (1.07 [0.67,1.7]). There was no difference in hospital mortality compared to steroids alone (aOR 0.68, 95% CI 0.43,1.09 for IL6R antagonist, aOR 1.23, 95 % CI 0.72,2.11 for combination). The findings of sensitivity analysis were consistent with the primary analysis. The rate of liver dysfunction was higher in the IL6R antagonist (p=0.038), while the rate of bacteremia did not differ among the three groups. Conclusions: We observed no difference in outcomes between mechanically ventilated adult ICU patients who received IL6R antagonists, steroids, or combination therapy and those who received IL6R antagonists or low or high dose steroids. Further trials are needed to evaluate high-dose steroids as substitutes for IL6R antagonists in resource-limited settings.

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) the primary analysis; no difference was observed between IL-6R antagonists alone or in combination compared 243 to using steroids alone. There was no difference in hospital mortality compared to steroids alone ( aOR 0.68 , 244 95% CI 0.43,1.09 for IL6-R antagonist, aOR 1.23, 95 % CI 0.72, 2.11 for combination) [ Figure 2B ]. Cox proportional hazard regression was used to assess factors associated with mortality (Figure 3, Panels A  246 and B). Discharge and mortality were included as competing risks. The hazard of mortality was not significantly 247 different between patients who used IL-6R antagonists (HR = 0.9, p>0.05) or those who used both therapy (HR 248 = 0.84, p>0 .05) and patients who used only steroids. Similarly, the hazard of ICU discharge was not significantly 249 different between patients who used IL-6R antagonists (HR = 1.4, p>0.05) or those who used both therapy (HR 250 = 0.0.85, p>0 .05) and patients who used only steroids. The Cox proportional hazard model for ICU discharge 251 showed no significant difference in the probability of discharging alive from ICU in patients treated with IL-6R 252

antagonists (HR 1.36, 95% CI 0.95, 1.93, p=0.089) or combination therapy (HR 0.85, 95% CI 0.54, 1.34, p=0.484 ) 253 compared to those treated with steroids alone. Other variables with coefficients less than 1 (old age, 254 overweight, and presence of cardiovascular diseases) indicate a lower hazard of leaving ICU alive. Binary logistic 255 regression was used to assess whether the 28-day-mortality was significantly different between patients who 256 received high or low-dose steroids and those who received IL-6R antagonists (alone or combined). No 257 significant association was observed between the use of steroids (low-dose or high-dose) and mortality (eTable 258

Unweighted and weighted Kaplan-Maier estimates were constructed to assess the association between 260 treatment with hospital and ICU LOS before and after IPTW. After IPTW, no statistically significant differences 261 were observed between the groups (p=0.52). In adjusted analysis, patients who received IL-6R antagonists 262 were more likely to experience liver dysfunction (23.9%) than those who received steroids (14.6 %) or 263 combination therapy (11.9%) (p=0.038). High troponin levels were reported in patients who received 264 combination therapy. There was no difference in the overall incidence rate of bacteremia among the three 265 groups. Linear mixed modeling and linear marginal trends were used to assess changes in the PF ratio and 266

showed that the use of IL-6R antagonists or combination therapy was not associated with significantly 267 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 different changes in the PF ratio as compared to the use of steroids alone. Exploratory analyses including SOFA 268 and highest FiO2 on risk adjusted mortality and VFD showed comparable finding to primary analysis. (eTables 269

Discussion 271 We reported the clinical characteristics and outcomes of adult ICU required iMV, 272 and received either monotherapy with IL-6R antagonists or steroids or combination therapy within a large, 273 multinational registry. We observed no significant difference in outcomes among the three groups and among 274 those who received IL-6R antagonists compared to low-and high-dose steroids. The results of the present 275 study motivate future comparative studies between IL-6R antagonists and high-dose steroids. We consider 276 this is relevant during time of shortage in resource-limited settings, or with the huge demand for tocilizumab 277 for other indications, such as chimeric antigen receptor T-cell (CAR-T)-induced cytokine release syndrome, 278

Castleman disease, and rheumatoid arthritis. Moreover, IL6-R antagonists are expensive medications and may 279 be available at only a limited number of hospitals. We have provided insights on whether high-dose steroids 280 would act as a substitute for tocilizumab, saving thousands of dollars and preserving it for other indications. 281

Although the observational nature of our study precludes the examination of potential interactions, we 282 consider our results useful for generating hypotheses and to bridge the knowledge gap regarding different 283 steroid regimens with IL-6R antagonists. 284 IL-6R antagonists have been investigated in previous studies with conflicting results. Given the wider 285 accessibility of tocilizumab, this agent was the focus of prior trials. Randomized data available on the use of 286 tocilizumab in COVID-19 patients neither overwhelmingly support nor convincingly refute routine use [23] . 287 Some trials failed to demonstrate a reduction in mortality and other trials found that tocilizumab lowered the 288 incidence or duration of ICU and hospital stays or lowered the composite rate of MV and death [24, 25] . Our 289 findings are similar to the results of several RCTs which did not demonstrate all-cause mortality benefit in 290 patients receiving tocilizumab [24] [25] [26] [27] [28] . In contrast, the REMAP-CAP trial showed that the use of either 291 tocilizumab or sarilumab reduced both mortality and time to ICU discharge, and increased the number of 292 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 organ support-free days compared to no immune modulation in ICU patients requiring respiratory support 293 [9] . Moreover, a recent study published in Chest showed superior survival outcomes for patients treated with 294 a combination of corticosteroids and tocilizumab compared with patients treated with corticosteroids alone 295 (up to 15 mg dexamethasone) (HR, 0.66; 95% CI, 0.53,0.83; p=0.004) [29] . The reasons for these differences 296 include varying degrees of respiratory dysfunction among patients enrolled in each study, racial and ethnic 297 differences in the populations studied, corticosteroid use, inclusion of sarilumab, and differences in the use 298 of other co-interventions because the trials were conducted at different times during the pandemic as 19 treatment practice evolved [30] . The findings of our study may be explained by different types and doses 300 of steroids including high-dose steroids in our analysis while REMAP-CAP included fixed dose/duration 301 steroids and shock dependent hydrocortisone. In RECOVERY, there was no difference in duration of iMV or 302 VFD as only 185 patients had such ventilation successfully removed within the first 28 days [10] . Although our 303 sample size is limited and definitive conclusions cannot be made regarding the effectiveness of the different 304 therapies, further adequately powered studies are warranted to test our hypothesis. 305

The RECOVERY trial suggested that dexamethasone 6 mg IV daily resulted in a lower death rate than 306 the usual care group in patients receiving iMV [5] . After results from the RECOVERY trial became publicly 307 available, further steroid trials were stopped prematurely because the equipoise for withholding 308 corticosteroids was no longer present, and corticosteroids became the standard care for ICU patients with 309 COVID-19 requiring MV or supplemental oxygen [31] [32] [33] [34] . On the other hand, the Italian National Institute for 310

Infectious Diseases recommends a 10-day regimen: a 5-day full dose of methylprednisolone 1 mg/kg daily or 311 dexamethasone 20 mg daily (defined as high-dose steroids in our study). This regimen is lower than the fixed 312 dexamethasone dose used in the RECOVERY trial and that described in the literature for non-COVID ARDS 313 [13, 35] . Prior studies have suggested that moderate-to-high dose steroid regimens resulted in a greater 314 reduction in mortality, shorter ICU LOS, lower organ dysfunction, lesser requirement for MV or renal 315 replacement therapy, and no increase in medical or infectious complications when compared to low-dose 316 regimens in ICU COVID-19 patients [33, 36] . 317 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Regarding the inflammatory marker, majority of the patients in our study had a baseline CRP level of 318 greater than 75 mg/L at baseline, indicating that hyperinflammatory phenotypes and high degrees of critical 319 illness, supporting the mechanism of immunomodulators. Nonetheless, recent studies have shown that 320 systemic levels of cytokines in COVID patients may not be as high as seen with sepsis and ARDS. It may be that 321 local inflammation, as evidenced by respiratory dysfunction, is a more useful indicator of which patients will 322 benefit from IL-6 inhibition [37] . Although COVID-19 treatments were not used uniformly prior to matching 323 and patients did not receive up-to-date standards of care, especially in the early pandemic phase, we utilized 324 rigorous methods to match the three groups concerning the use of anticoagulation, hydroxychloroquine, 325 antiviral (including remdesivir), and azithromycin. 326

Patient selection, timing, and dose of immunomodulator are important considerations in optimizing 327 the effectiveness. The optimal administration time may be at onset of systemic hyperinflammation from the 328 host immune response and before the onset of multi-system organ failure [38] . This is consistent with several 329 studies suggesting the lack of benefit or potential harm if tocilizumab was administered "too early" (due to 330 risk of viral replication) or "too late" [39] . The initial RCTs suggested that the maximum benefit from IL-6R 331

antagonists was seen when administered to rapidly deteriorating patients with signs of inflammation, as seen 332 in the most severely ill patients with COVID-19 with the highest death risk. In the REMAP-CAP, > 75% of the 333 participants received IL-6 inhibitors within three days of hospital admission [9] . In our study, the time of 334 steroids and IL-6R antagonists administration was in agreement with the prior findings where the majority 335 were administered in the first 48 h of ICU admission. Of note, patients who received IL-6R antagonists or 336 steroids within ICU days 0 or 1 were included for the target trial approach. Moreover, the number of 337 tocilizumab and sarilumab doses that were administered in our study were comparable to those reported in 338 the literature where the majority of the population received one dose. 339

There is concern regarding additive immunosuppression with administration of steroids and IL-6R 340

antagonists. In our study, we found no difference in the rate of superinfections between the three groups. 341

Additionally, it was unclear from our analysis whether the infection was the result of a prolonged ICU stay or 342 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 repeated administration of IL-6R antagonists with steroids. Importantly, this study reinforces the risk of liver 343 injury due to IL-6 inhibition. In the REMAP-CAP, an assessment of the safety was limited by the low number 344 of AEs. Clinicians should be aware of these effects and should weigh the risks and benefits of treatment. 345

Whether this risk is intensified with repeated administration of IL-6R antagonists or related to patients' critical 346 presentation warrant investigation in future studies. 347

The strengths of this study lie in the large number of patients, and multinational nature. Prior studies 348 were limited to two or three hospitals and restricted by geography. Our study used data from the largest 349 COVID-19 registry across the globe and represented a spectrum of intensive care with racially and ethnically 350 diverse cohorts, thereby maximizing generalizability. By including a large number of hospitals, we also 351 identified considerable variation in practice patterns that we accounted for risk-adjustments in our statistical 352 analysis. Moreover, we included patients with laboratory-confirmed COVID-19 PCR tests, thereby minimizing 353 the selection or surveillance bias at each center. Furthermore, we have strengthened the validity of our 354 analysis by using MSM, which allows for proper adjustment of time-dependent confounding variables, 355 adjustment for immortal time bias, and indication bias [20, 40] . We also conducted a novel method "target 356 trial approach" to reduce the immortal bias associated with observational studies [17, 22] . 357

We acknowledge several limitations. First, randomized controlled trial are critical for exploring the 358 causal effect of treatments and clinical outcomes and accurately quantifying the risks. Second, our sample size 359 was limited, indicating that there were risks of type II errors. Although we used the best available method to 360 compare well-balanced groups, controlling for confounders in observational study may be incomplete despite 361 all efforts. Moreover, there was a large proportion of incomplete data for SOFA and APACHE II scores, because 362 of the heavy burden experienced by participating clinicians during the pandemic. We also did not report the 363 steroid and IL-6R antagonist administration time from symptom onset and we did not address the potential 364 role of IL-6R antagonists in preventing MV or the role of IL-6 level (available only in 24 patients of our cohort) 365 in predicting IL-6R antagonist responses, all of which are important questions that warrant further 366 investigation. In addition, the standard treatment protocol for COVID-19 evolved since the analysis of this 367 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 study, which may have impacted the clinical characteristics and outcomes for patients who presented in the 368 later phase of the pandemic. The steroid duration was highly variable, and data entry was inconsistent. Thus, 369

we were unable to completely minimize the effect of this important variable. We also did not have detailed 370 documentation on the AEs and we were unable to collect data on the time to viral clearance. Finally, while all 371 patients in our cohort had a minimum follow-up time of 28 days, additional follow-up may help characterize 372 the long-term sequelae, especially the incidence of invasive fungal infection, pneumocystis pneumonia, and 373 multi-drug resistance organisms. Going forward, we propose to include research findings, including ours, into 374 the VIRUS web-based decision aid to evaluating the risk, benefit, and burden of specific interventions 375 considering prior knowledge, clinical context, and preference, and also to include clinical decision support 376 tools in the future to determine how the aforementioned parameters are modified by new research findings. 377

In this study, we observed no significant difference in clinical outcomes between patients who received 379 monotherapy with an IL-6R antagonist or corticosteroid versus combination therapy with both. There was no 380 significant difference between patients who received IL-6R antagonists and those who received low-and high-381 dose steroids. While observational studies cannot suggest causality, further randomized clinical trials are 382 needed to evaluate the clinical outcomes and safety of high-dose steroids to be used as substitutes during a 383 time of shortage in resource-limited settings for critically ill COVID-19 patients. 384

We thank the SCCM Discovery VIRUS data registry and the Collaborative Co-authors listed in Supplementary 386 file 2 for providing and maintaining the database of hospitalized COVID-19 patients which made this study 387 possible. We are particularly grateful and thankful to Professor Yaseen M Arabi at King Saud bin Abdulaziz 388

University for Health Sciences and King Abdullah International Medical Research Center for inputs and review 389 of this manuscript. We thank the ICU physicians, nurses, respiratory therapists, physiotherapists, pharmacists 390 across the globe for their efforts to save the lives of ICU patients and their braveness in fighting the COVID-19 391 pandemic. 392 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint 393 Authors contribution 394 MA: proposed the study, led the manuscript writing and did the data collection. AK: made the statistical analysis of 395 this study. All authors made substantial contributions to the concept, design, data collection, and has further 396 participated in the analysis and interpretation of the data. All authors participated revised the manuscript for 397 important intellectual content and approved the final version to be published. We confirmed that the authorship 398 followed the uniform requirements for manuscripts submitted to biomedical journals. 399

The datasets used and analyzed during the current report are available from the corresponding 401 author on reasonable request. 402 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint Data presented as n (%) unless otherwise specified. N (%) may differ due to approximation ¶ Each individual gets its own weight that is used for further analysis. Multiplication by these weights can usually results in decimals.

Abbreviation: ARDS: Acute respiratory distress syndrome ; CVD : cardiovascular diseases, COPD: Chronic obstructive pulmonary disease ; IPTW: Inverse probability weighting, SMD: standardized mean difference; SD: standard deviation; P:F: ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint Figure 2 . Association between treatment modality, VFD, and 28-day mortality Panel A.

Panel A. Association between treatment modality and ventilator-free days Panel B. Association between treatment modality and 28-day mortality Estimates in panel A represent adjusted incident rate ratio (aIRR) . Estimates in panel B represent adjusted odds ratio (aOR) Missing data outcomes in sensitivity analysis to emulate a target trial: 4 patients missing 28-day mortality status and 15 missing duration of Imv Abbreviation: VFD ventilation free days, IPTW: Inverse probability of treatment weight, IPTW-SOFA: Inverse probability weighting with added Sequential Organ Failure Assessment (SOFA), IPTW-Highest FiO2: Inverse probability weighting with added fractional inspired oxygen concentration -Marginal structural models (MSM) was used to adjust for time-dependent confounders. Observations were weighted by the inverse probability of treatment weight (IPTW).

-In sensitivity analysis to emulate a target trial: eligible patients on MV were included if they received IL-6R antagonists or steroids within ICU days 0 or 1. Patients who died within the first 48 hours were also excluded.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. The normality of residuals were inspected to ensure good model fit for the linear regression model.

ß is the log of incident rate ratio. if 0 then it is not significant . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. These are the included hospital per country in the VIRUS registry . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint

Severity of illness was evaluated using Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHEII) scores.

The worst value for baseline laboratory tests was chosen. These data were collected within the first 24 h after admission to the ICU. If that data were not available, then data closest to admission were recorded.

Recorded as the number of calendar days from intubation to extubation or until ICU discharge, or death whichever occurs first. The median ventilatorfree days was calculated as calendar days with no ventilator support to day 28. Participants who die before day 28 are assigned zero free days.

Identified based on positive blood, urine, and sputum cultures. Only infections occurring after administration of anti-IL6 or steroids were considered. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint

International System of Units (SI) were used to represent laboratory data unless otherwise specified. The data were checked for integrity and outliers in the laboratory data (numbers > the 99th percentile) were removed based on clinical judgment and whether the extreme values were clinically plausible. For dichotomous outcomes, the corresponding mixed effects model, namely a mixed effects logistic regression gives fixed effects coefficients that have an interpretation conditional on the random effects. Most often, this is not the interpretation we want. The GEE approach does give coefficients with a marginal / population-averaged interpretation.

However, an additional practical point that also need to consider is missing data and almost always we have to deal with incomplete data. With regard to this point, mixed models give valid results under the less stringent missing at random assumption compared to the (standard not weighted) GEE that give valid results under the less realistic missing completely at random assumption.

Taking both points (i.e., interpretation and missing data) into account, would most often like to fit a mixed model to be more protected for the missing data but want to obtain parameters that have a population averaged

interpretation. An early solution towards this direction was the marginalized mixed models proposed by Heagerty, but, in general, these are computationally intensive to fit. A more recent approach that seems to solve the problem . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint has been proposed by Hedeker et al. This is implemented in the function marginal_coefs() of the R package GLMMadaptive.

The fixed effects estimates in mixed models with nonlinear link functions have an interpretation conditional on the random effects. However, often we wish to obtain parameters with a marginal / population averaged interpretation, which leads many researchers to use generalized estimating equations, and dealing with potential issues with missing data. Nonetheless, recently Hedeker et al. have proposed a nice solution to this problem. Their approach is implemented in function marginal_coefs(). For example, for model fm we obtain the marginalized coefficients.

The function calculates the marginal log odds ratios in our case (because we have a binary outcome) using a Monte Carlo procedure with number of samples determined by the M argument. Standard errors for the marginalized coefficients are obtained by setting std_errors = TRUE in the call to marginal_coefs(), and require a double Monte Carlo procedure for which argument K comes also into play.

Generalized estimating equations (GEE) were constructed to evaluate the impact of the treatment (t) on the outcome (d) and to handle the time-varying covariate (v) in the panel dataset. Since the outcome was a continuous variable, a generalized linear Gaussian family with identity link was used. Auto-regressive (AR1) correlation structure was selected since this was a time series (panel) data; we expected the correlation to decay as the outcome values were farther away from the time of interest.

Covariates included in the model were age, sex, ethnicity, asthma/COPD, ARDS grade (none, mild, moderate or severe) at admission, respiratory failure at admission, history of CVD (diabetes, hypertension, coronary heart diseases or congestive heart failure), and the baseline lowest arterial oxygen concentration. Other covariates included the use of any anticoagulation, therapeutic anticoagulation, hydroxychloroquine, azithromycin, and antivirals. The effect of adding steroids, IL-6 antagonists was assessed by including each variables as a dummy coded variable in the marginal model. In addition, an interaction term was added to the model to assess whether the combination of both drugs was associated with a statistically significant effect size.

inverse probability weighting (IPTW) are weights assigned to each observation across time conditioned on the previous exposure history, which are then multiplied to generate a single weight for a subject. Similar to conventional propensity score estimation, IPTW is generated using either a logit or probit model that regresses covariates to a treatment group (exposure) variable. With IPTW, the previous exposure history is incorporated to the propensity score estimation, which is time-varying. Standardized weights in a longitudinal setting are is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint denominator but not in the numerator. However, the non-time varying (also known as fixed-time) covariates are captured in both the numerator. Due to the longitudinal nature of the data, the GLMMadaptive package was used for model fitting. The Package GLMMadaptive provides a suit of functions for fitting and post-processing mixed effects models for grouped/clustered outcomes which have a distribution other than a normal distribution. In particular, let yi denote a vector of grouped/clustered outcome for the i-th sample unit (i=1,…,n).

Standardized mean difference (SMD) were reported for comparison between cohorts before and after matching

The generalized boosted model (GMB) creates a separate level during matching called NA and creates weights based on the distribution of missing values. So basically it considers NA as a level of its own. The weights are created for all respondents and are taking the missing values into consideration. Imputation requires that data is missing at random which is not the case here. Moreover, the variables we used had few missing values so there is no problem which would not have been the case if we used the SOFA and APACHE which had a lot of missing data.

The populations are weighed by the probability of receiving treatments based on other confounders. The weights were produced using generalized boosted models and these weights were used when doing further analysis. The pseudo population is the sum of weights for each group rather than considering each observation as 1. Thus, the numbers can increase or decrease compared to the initial number of the group depends on the assigned weights.

The aim to emulate randomized trial to create a pseudo study cohort, where the weighted version can balance off the covariate bias and mimic a randomized treatment assignment situation . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint Abbreviation: ARDS: Acute respiratory distress syndrome ; COPD: Chronic obstructive pulmonary disease SD: standard deviation; P:F: ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 0 (0) Data presented as n (%) unless otherwise specified Abbreviation: ARDS: Acute respiratory distress syndrome ; P:F: ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Supplementary . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint Documented ventilator associated pneumonia (VAP) 15 (5.2) 0 (0) 4 (10.5) 0.045 13 (3.9) 3 (2.9) 2 (3.7) 1 Data presented as n (%) unless otherwise specified ¶ percentage calculated based on available data for patients with computerized tomography (CT) chest scan . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint Supplementary . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. Data presented as n (%) unless otherwise specified . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. 102 Data presented as n (%) unless otherwise specified. N (%) may differ due to approximation ¶ Each individual gets its own weight that is used for further analysis. Multiplication by these weights can usually results in decimals Abbreviation: CPR: Cardiopulmonary resuscitation; DNR: Do-not-resuscitate order; DNI: Do Not Intubate; IV: intravenous . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint Data presented as n (%) unless otherwise specified . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Supplementary Data presented as median (IQR) . Units presented as SI units as following : PaO2 in mmHg ; ALT/SGPT, AST/SGOT, Alkaline Phosphatase, and Lactate Dehydrogenase (µkat/liter); bilirubin (µmol/liter); Ferritin (mcg/L); leukocytes (×10^9/liter); D-dimer mg/L; Procalcitonin (mcg/L); Fibrinogen (g/L); interleukin 6 (IL-6) (pg/ml); Lactate (mmol/liter); Platelet (x10^9/L) The following presented as conventional unit: Lymphocyte (% of white blood cells); C-reactive protein (mg/L) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Supplementary Data presented as mean (SD) . Units presented as SI units as following : PaO2 in mmHg ; ALT/SGPT, AST/SGOT, Alkaline Phosphatase, and Lactate Dehydrogenase (µkat/liter); bilirubin (µmol/liter); Ferritin (mcg/L); leukocytes (×10^9/liter); D-dimer mg/L; Procalcitonin (mcg/L); Fibrinogen (g/L); interleukin 6 (IL-6) (pg/ml); Lactate (mmol/liter); Platelet (x10^9/L) presented as conventional unit Lymphocyte (% of white blood cells); C-reactive protein (mg/L) Abbreviation: PF ratio: ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Supplementary Data presented as n (%) unless otherwise specified . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Supplementary weighting . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 13, 2021. + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + ++ + + + ++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Data presented as n (%) unless otherwise specified. N (%) may differ due to approximation ¶ Each individual gets its own weight that is used for further analysis. Multiplication by these weights can usually results in decimals . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Supplementary Data presented as n (%) unless otherwise specified . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 13, 2021. ß: estimate represents average change in PFO2 for each 1 unit change in the predictor i.e. the increase in the PF ratio for each 1 unit increase in the predictor for IL-6R antagonists, steroids, and combination group.

Linear mixed modelling is similar to linear regression. The coefficients represent the change in the outcome for each 1 unit change if the predictor is continuous. If the predictor is categorical, it represents the average change between the specified level and the reference category ¶The -33.64 means that the average PF ratio is lower by 33.64 in patients with severe ARDS compared to patients with no ARDS * This represents the average change in PF ratio per day in each of these groups for each 1 day increase in the ICU stay. for example, the 1.12 means that the average increase in the PF ration (per day) in patients who received both meds is higher by 1.12 units compared to patients who received steroids Linear mixed modeling considers clustering within patients. Time was included as the main effect of the model. The same covariates used for MSM were used in the mixed model to ensure consistency. PF ratio data were available for 482 patients. Estimated marginal trends were used to visualize the change in the ratio after adjusting for baseline factors (e.g., age and sex) and time-varying covariates, such as the use of anticoagulation. Missing values were not imputed. The interaction between time and medication use was also included in the model to assess whether the change in the PF ratio was significantly different between the groups.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint Supplementary Figure 2. Estimated marginal trend for the change in PF ratio across groups.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.12.21255323 doi: medRxiv preprint

Linear mixed modelling was used to assess whether the change in lab values across time was significantly different between groups. The interaction between time and medication was included in the model. The same variables used for IPTW were used for the analysis. Only results for the interaction are shown. Data for IL-6 was not sufficient N represents the number of available patients for the analysis . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Supplementary . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

File 2: Collaborative Co-Author List

Alay Nanavati, Risa Mrozowsk LifeBridge Health/Sinai and Northwest Hospitals: Namrata Nag

Rohan Mehta Mercy Hospital, Saint Louis: Chakradhar Venkata, Miriam Engemann, Annamarie Mantese Millard Fillmore Suburban Hospital